Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

TSE:4502
TSE:4502Pharmaceuticals

Does Takeda Pharmaceutical (TSE:4502) Still Offer Value After Its 33.7% One-Year Rally?

For investors considering whether Takeda Pharmaceutical at ¥5,800 represents fair value or a potential bargain, this article breaks down the key signals behind the share price. The stock has delivered a 33.7% return over the last year and 18.0% year to date, even though the last 7 days show a 1.2% decline and the last 30 days are roughly flat at 0.2%. Recent coverage has focused on Takeda Pharmaceutical in the context of broader healthcare and pharmaceutical sector themes. These themes can...
SEHK:933
SEHK:933Luxury

Viva Goods (SEHK:933) Profit Rebound Tests Long Term Earnings Decline Narrative

Viva Goods (SEHK:933) has kicked off FY 2025 with first half revenue of HK$4.8b and basic EPS of HK$0.0314, while the trailing twelve months show revenue of HK$10.3b and basic EPS of HK$0.0147 as the group settles back into profit. Over the past three reported half year periods, revenue has moved from HK$5.1b in 1H 2024 to HK$5.3b in 2H 2024 and HK$4.8b in 1H 2025, with basic EPS shifting from HK$0.0198 to a loss per share of HK$0.0160 and then to HK$0.0314 as margins turned positive again...
NYSE:NNI
NYSE:NNIConsumer Finance

Is It Too Late To Consider Nelnet (NNI) After Its 1-Year 16.9% Share Price Gain?

If you are wondering whether Nelnet's current share price still offers value or if most of the opportunity is already priced in, this article will help you frame that question clearly. With the stock at US$129.60 and returns of 1.2% over 7 days, 0.5% year to date, and 16.9% over 1 year, recent performance provides a useful backdrop before looking at what the business might be worth. Recent news coverage about Nelnet has focused on its role as a diversified financial services company and how...
NYSE:GM
NYSE:GMAuto

General Motors Tests Hands Free System As Valuation Signals Possible Upside

General Motors (NYSE:GM) has begun supervised public road testing of its next generation hands free, eyes off automated driving system on highways in California and Michigan. More than 200 GM vehicles are running the technology in live traffic as part of this test phase. GM plans a commercial rollout of the system on the 2028 Cadillac Escalade IQ, signaling its intent to bring higher automation levels to a flagship model. For investors, this move sits at the intersection of GM's core auto...
NasdaqGS:VFS
NasdaqGS:VFSAuto

Assessing VinFast Auto (NasdaqGS:VFS) Valuation After Analyst Meetings Highlight Long Term EV Ecosystem Push

VinFast Auto (NasdaqGS:VFS) is back in focus after recent analyst meetings highlighted its emphasis on long-term expansion, ecosystem buildout around charging and ride-hailing, and the backdrop of strong reported electric vehicle delivery figures. See our latest analysis for VinFast Auto. The recent analyst meetings and strong delivery updates have come against a weaker trading backdrop, with a 90 day share price return of 14.37% decline and a 3 year total shareholder return of 70.81%...
NasdaqGM:AAOI
NasdaqGM:AAOICommunications

Is It Too Late To Consider Applied Optoelectronics (AAOI) After Its Recent Share Price Surge?

Wondering whether Applied Optoelectronics at around US$113.90 is still offering value or has already priced in much of its story? This article walks through what the current valuation signals are really saying. The share price has recently been volatile, with returns of 31.9% over 7 days, 120.4% over 30 days, 187.6% year to date, 423.2% over 1 year and a very large gain over 3 years and 5 years based on the data provided. Recent coverage has focused on these sharp moves in the share price...
NYSE:GMED
NYSE:GMEDMedical Equipment

A Look At Globus Medical (GMED) Valuation After Recent Pullback And Mixed Return Profile

Stock performance snapshot and business profile Globus Medical (GMED) is on investors’ radar after a recent pullback, with the stock showing a 1-day return of a 1.10% decline and a past month return of a 4.79% decline. Over the past 3 months, Globus Medical has recorded a 2.47% decline, while the 1-year total return stands at 12.55%. Year to date, the stock is down 1.20%, giving investors mixed signals on short-term sentiment. The company has a market value of about US$11.80b and focuses on...
ENXTAM:HAL
ENXTAM:HALDiversified Financial

Assessing HAL Trust (ENXTAM:HAL) Valuation After FTSE All-World Index Inclusion

Index inclusion puts HAL Trust in focus HAL Trust (ENXTAM:HAL) has been added to the FTSE All-World Index (USD), an event that can alter trading patterns as index funds and passive products adjust their holdings. For existing and potential shareholders, the inclusion raises practical questions around liquidity, valuation, and how the stock’s recent return profile compares with increased index linked demand. See our latest analysis for HAL Trust. The index inclusion follows a period of strong...
NasdaqGS:LKFN
NasdaqGS:LKFNBanks

Cluster of Insider Purchases by Director Welch Could Be A Game Changer For Lakeland Financial (LKFN)

In recent weeks, Lakeland Financial Corporation director M. Scott Welch executed three open‑market purchases of LKFN common stock between February 27 and March 12, 2026, marking his first meaningful increase in beneficial ownership since March 2025. This cluster of insider buying stands out as a clear signal that a key board member is willing to commit additional personal capital amid sector uncertainty. We’ll examine how this recent insider buying flurry by Director M. Scott Welch shapes...
NasdaqCM:OCGN
NasdaqCM:OCGNBiotechs

Is Ocugen (OCGN) Pricing Make Sense After Its Volatile Multi‑Year Share Price Swings

If you are wondering whether Ocugen's current share price still makes sense after a strong run, the key question is how that price lines up with the underlying value of the business. Ocugen shares, which last closed at US$1.92, have had a mixed but attention grabbing run, with a 21.6% decline over the last 7 days, a 20.0% gain over 30 days, 39.1% year to date, 168.6% over 1 year and 131.3% over 3 years, set against a 71.6% loss over 5 years. Recent news coverage has focused on Ocugen's...
NasdaqGS:UNIT
NasdaqGS:UNITTelecom

Did Kinetic’s Rural Fiber Accolade Just Reframe Uniti Group’s (UNIT) Fiber-First Investment Narrative?

Earlier in 2026, Uniti’s Kinetic business unit was named CNET’s Best Rural Fiber Internet Provider for the second consecutive year, as it pursues a multi‑year fiber build aimed at reaching about 2.3 million homes by the end of 2026 and roughly 3.5 million homes by 2029. This recognition highlights Kinetic’s role in extending multi‑gigabit connectivity to rural and suburban communities, underlining Uniti’s focus on digital equity and infrastructure-led growth. We’ll now examine how Kinetic’s...
NYSE:NRP
NYSE:NRPOil and Gas

A Look At Natural Resource Partners (NRP) Valuation After S&P TSX Global Mining Index Inclusion

Index inclusion puts Natural Resource Partners (NRP) on more investors' radar Natural Resource Partners (NRP) was recently added to the S&P/TSX Global Mining Index, an event that can increase its visibility as index tracking funds and institutional investors review their allocations. See our latest analysis for Natural Resource Partners. That index inclusion comes after a period of strong momentum, with a 90 day share price return of 21.30% and a 1 year total shareholder return of 22.54%,...
NYSE:BG
NYSE:BGFood

A Look At Bunge Global (BG) Valuation After Strong Recent Share Price Momentum

Bunge Global (BG) has drawn fresh attention after recent share price moves, with the stock up about 1.8% over the past month and roughly 40% over the past 3 months. See our latest analysis for Bunge Global. The recent 90 day share price return of 39.9% and 1 year total shareholder return of 74.2% suggest momentum has been strong, even if the latest 7 day share price move has paused that trend. If this kind of move has you thinking about what else might be setting up for strong performance, it...
SEHK:2342
SEHK:2342Communications

Comba Telecom Systems Holdings (SEHK:2342) Returns To Profit In 1H 2025 Challenging Bearish Narratives

Latest FY 2025 Earnings Snapshot Comba Telecom Systems Holdings (SEHK:2342) has just posted its FY 2025 first half numbers, with revenue of HK$2,199.2 million and net income of HK$61.8 million, translating into basic EPS of HK$0.021. Looking back over the last three reported half year periods, revenue moved from HK$2,343.5 million in 1H 2024 to HK$2,184.8 million in 2H 2024 and now HK$2,199.2 million in 1H 2025. Net income shifted from a loss of HK$158.4 million and then HK$405.8 million in...
BIT:A2A
BIT:A2AIntegrated Utilities

A Look At A2A (BIT:A2A) Valuation After 2025 Earnings And Dividend Announcement

Dividend announcement and earnings set the tone for A2A (BIT:A2A) A2A (BIT:A2A) has given investors fresh information to assess, pairing its full year 2025 earnings release with an annual dividend announcement of €0.1040 per share scheduled for payment on 20 May 2026. See our latest analysis for A2A. The share price has been choppy in the short term, with a 1 day share price return of 1.87% and a 7 day share price return showing a 3.81% decline. The 1 year total shareholder return of 11.57%...
NYSEAM:BMNR
NYSEAM:BMNRSoftware

A Look At Bitmine Immersion Technologies (BMNR) Valuation After Recent Mixed Share Price Performance

Bitmine Immersion Technologies (BMNR) has drawn fresh attention after recent trading left the stock with mixed returns. The shares fell 10.5% over the past week, while posting a gain over the past month. See our latest analysis for Bitmine Immersion Technologies. At a latest share price of $20.80, Bitmine Immersion Technologies has seen weak short term momentum, with a 1 day share price return of 2.21% decline and a 90 day share price return of 29.13% decline. This contrasts with a 1 year...
NasdaqGS:NTNX
NasdaqGS:NTNXSoftware

Is Nutanix (NTNX) Pricing Look Attractive After Recent Share Price Weakness?

If you are wondering whether Nutanix at around US$39.31 is a bargain, expensive, or somewhere in between, the starting point is to look closely at what the current price actually reflects. The stock has seen a 5.7% decline over the last 7 days and is down 22.3% year to date, yet it still shows a 58.4% return over 3 years and 52.0% over 5 years. This combination can leave the current valuation looking unclear. Recent news coverage has focused on Nutanix as a key name in software and cloud...
NasdaqGS:CIFR
NasdaqGS:CIFRSoftware

Hyperscale Campus Lease And New Credit Facility Could Be A Game Changer For Cipher Digital (CIFR)

Cipher Digital recently executed its third data center campus lease, a 15-year agreement with an investment-grade hyperscale tenant to develop and deliver a new high-performance computing facility at one of its existing sites. At the same time, the company secured an undrawn US$200.00 million revolving credit facility with an additional US$50.00 million accordion, strengthening liquidity and underpinning its shift toward high-performance computing infrastructure alongside bitcoin...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Is Madrigal Pharmaceuticals (MDGL) Still Attractive After Mixed Returns And Strong DCF Upside?

Investors may be wondering whether Madrigal Pharmaceuticals, at around US$445 a share, still offers value or if most of the opportunity has already been priced in. The stock has recent returns of 0.4% over 7 days, 2.3% over 30 days, a 25.1% decline year to date, and a 29.6% return over 1 year. This mixed performance can leave investors unsure how to read the risk and reward trade off. These moves sit against a backdrop where Madrigal Pharmaceuticals continues to attract attention in the...
NasdaqGS:RVMD
NasdaqGS:RVMDBiotechs

Is It Too Late To Consider Revolution Medicines (RVMD) After A 148% One Year Surge?

If you are wondering whether Revolution Medicines at around US$95.52 is still offering value after a strong run, the key question is how its current price stacks up against a range of valuation checks. The stock has seen a 3.6% decline over the past 7 days and a 6.2% decline over the past 30 days, yet it shows returns of 20.9% year to date and 148.4% over the last year, with a very large 3 year return and a 117.4% return over 5 years. Recent news has focused on Revolution Medicines as a high...
NasdaqGS:GILT
NasdaqGS:GILTCommunications

Cloud-Based Virtual Modem Demo With AWS Could Be A Game Changer For Gilat Satellite Networks (GILT)

In March 2026, Gilat Satellite Networks announced that its defense division, together with Amazon Web Services, SES Space and Defense and the WAVE Consortium, completed a joint demonstration at the SATELLITE 2026 conference of a virtualized, FPGA-accelerated satellite modem running on AWS cloud infrastructure and linked to a Gilat Aquarius Pro DS modem. This proof-of-concept showed how moving modem functions into software running over standardized, open interfaces could increase flexibility,...
SEHK:3933
SEHK:3933Pharmaceuticals

United Laboratories International Holdings (SEHK:3933) Margin Compression Challenges Bullish Narrative

How United Laboratories International Holdings' Latest Numbers Set the Stage for the Narrative United Laboratories International Holdings (SEHK:3933) has put up a busy FY 2025 first half, with revenue of about C¥7.5b and basic EPS of C¥1.04 sitting against trailing twelve month revenue of roughly C¥14.1b and basic EPS of C¥1.69. Investors are sifting through what the shift in earnings power really means. Over the last three reported half year periods, revenue has moved from C¥7.2b in 1H 2024...